Stay updated on Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page
- Check7 days agoChange DetectedAdded 'Gastric cancer' as a topic label and included a 'Genetic and Rare Diseases Information Center' resource in the Resources section. This supplements patient information without modifying trial details.SummaryDifference0.2%

- Check14 days agoChange DetectedThe page now shows a new revision tag: Revision: v3.4.2. The older notice about lapse in government funding and operating status has been removed.SummaryDifference0.5%

- Check21 days agoChange DetectedThe update consists of an administrative notice about government funding and a revision tag from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedThe update primarily adds UI elements and expands glossary/metadata labels (Show glossary, IPD data planning terms, and related MeSH terms) across the page, with no changes to the core study details, eligibility criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference48%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This is a minor version update with no visible changes to the study content.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter updates include the addition of 'Revision: v3.3.3' and the removal of the 'HHS Vulnerability Disclosure' link along with the earlier 'Revision: v3.3.2' label. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.